Aintree Centre for Gastroenterology, University Hospital Aintree, Liverpool, UK.
Expert Rev Pharmacoecon Outcomes Res. 2006 Aug;6(4):471-82. doi: 10.1586/14737167.6.4.471.
Inflammatory bowel diseases (IBDs) are chronic, relapsing conditions that have no permanent drug cure, may occur for the first time in early life and have the potential to produce long-term morbidity. In the era of emerging biological drug therapies, the costs associated with IBD have attracted increased attention. This review considers the available information on the macroeconomics of ulcerative colitis and Crohn's disease. In relation to direct medical costs, the consistent findings are: hospital (in-patient) costs are incurred by a minority of sufferers but account for approximately half the total cost; and drug costs contribute less than a quarter of the total healthcare costs. Data for levels of costs associated with lost productivity are more variable, but some studies have estimated that 'indirect' costs falling on society exceed medical expenditures. Lifetime costs for IBD are comparable to a number of major diseases, including heart disease and cancer. Over the next 5-10 years, the contribution of drug costs to the overall profile of cost-of-illness will change significantly as biological therapies play an increasing role. A key economic question is whether the health gains realized from exciting new drugs will also lead to reduced expenditures on hospitalization and surgery.
炎症性肠病（IBD）是一种慢性、复发性疾病，目前尚无永久性药物治愈方法，可能首次发生于生命早期，并有可能导致长期发病。在新兴生物药物治疗时代，与 IBD 相关的成本引起了越来越多的关注。这篇综述考虑了溃疡性结肠炎和克罗恩病的宏观经济学方面的现有信息。关于直接医疗成本，有以下一致发现：少数患者会产生医院（住院）费用，但这些费用约占总成本的一半；药物成本不到总医疗费用的四分之一。与生产力损失相关的成本水平数据更加多变，但一些研究估计，社会承担的“间接”成本超过了医疗支出。IBD 的终身成本与一些重大疾病相当，包括心脏病和癌症。在未来 5-10 年内，随着生物疗法发挥越来越重要的作用，药物成本对疾病总成本构成的贡献将发生重大变化。一个关键的经济问题是，令人兴奋的新药带来的健康收益是否也会减少住院和手术的支出。
